Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0153690 (
bone metastases
)
6,382
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The plasminogen activator content of extracts of 14 prostatic carcinomas and the respective
bone metastases
was determined and found to be at an average 1.5 times higher in the extracts from
bone metastases
than in the primary tumors. Furthermore, the relative contribution of the two known types of plasminogen activators, urokinase-type (
u-PA
) and tissue-type (t-PA), was evaluated using specific antibodies. About 70% of the plasminogen activator activity in the primary tumors was inhibited by anti-urokinase IgG, whereas the same antibody nearly completely inhibited the plasminogen activator activity in extracts from
bone metastases
. Using antibodies against t-PA about 30% of the plasminogen activator activity could be quenched in extracts of primary tumors but less than 10% in extracts of
bone metastases
. Further studies revealed that the increased amount of
u-PA
in extracts of
bone metastases
is not caused by different extractability but is also reflected by a relative increase in the amount of
u-PA
demonstrable by immune histochemical techniques using anti-urokinase IgG. Upon purification, the predominant plasminogen activator from extracts of
bone metastases
could also be identified physicochemically as urokinase.
...
PMID:Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. 406 6
